STIMIT
Cambridge
About STIMIT
STIMIT's proprietary technology enables extended local delivery of cancer immunotherapy in the context of tumor resection, the standard of care for most patients with solid tumors. Concentrating and retaining the action of potent immunomodulators locally dramatically improves the efficacy and safety of these compounds relative to administration in solution, whether via intravenous or even intratumoral injection.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $20.6M
- Last round: Series Unknown (Dec 2020)
- Website: stimittx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Wellness
Social Profiles
Canonical: https://fsome.com/organization/stimit-71986 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.